Login
Calliditas Therapeutics AB logo

Calliditas Therapeutics AB

calliditas.se

No Longer Reporting

The company has not filed an annual or quarterly report since its FY2023 20-F, filed Apr 24, 2024. Its latest SEC filing is a SC 13D/A from Sep 23, 2024.

The sections below describe the company as of the FY2023 annual report.

What Did They Do?

Sells TARPEYO, a treatment for IgAN, through specialty pharmacies and licenses Nefecon to pharmaceutical partners; develops drug candidates for kidney, liver and cancer conditions.

How Did They Make Money?

Specialty pharmacies buy TARPEYO, with sales counted when the medicine is delivered. Pharmaceutical partners pay for Nefecon licenses when agreements are signed, with possible regulatory and commercial milestone payments and royalties tied to partner sales; Calliditas also earns fees for regulatory services as the work is performed.

FY2023 revenue

Who Were Their Customers?

Specialty pharmacies buy TARPEYO for dispensing to patients, while pharmaceutical partners license Nefecon for commercialization in Europe, China, Singapore, South Korea and Japan. Calliditas markets TARPEYO independently in the United States through a targeted sales team.

Did Revenues Turn Into Profits?

No. It lost SEK 466.2M in FY2023.

Operating income, FY2023
−31% of revenue
▲ +12% (Loss) vs FY2022 (−SEK 421.9M, −53%)
Net income, FY2023
−39% of revenue
▼ −13% (Loss) vs FY2022 (−SEK 412.3M, −51%)
Free cash flow, FY2023
−37% of revenue
▼ −43% (Loss) vs FY2022 (−SEK 313.9M, −39%)

Who Did They Compete With?

Competes with Travere Therapeutics, Novartis, Roche, Ionis Pharmaceuticals, Vera Therapeutics, Otsuka, Alpine Immune Sciences, BioCryst, Arrowhead Pharmaceuticals, Takeda, Alnylam Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, DiaMedica Therapeutics, MorphoSys, Kira Pharma, Intercept Pharmaceuticals, Cymabay Therapeutics, Ipsen, and GENFIT

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support